Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 703.39 million. The enterprise value is 664.02 million.
| Market Cap | 703.39M |
| Enterprise Value | 664.02M |
Important Dates
The last earnings date was Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 707.78 million shares outstanding. The number of shares has increased by 12.83% in one year.
| Current Share Class | 707.78M |
| Shares Outstanding | 707.78M |
| Shares Change (YoY) | +12.83% |
| Shares Change (QoQ) | -10.56% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 20.71% |
| Float | 696.57M |
Valuation Ratios
The trailing PE ratio is 89.72 and the forward PE ratio is 62.20.
| PE Ratio | 89.72 |
| Forward PE | 62.20 |
| PS Ratio | 2.19 |
| PB Ratio | 2.97 |
| P/TBV Ratio | 5.64 |
| P/FCF Ratio | 23.38 |
| P/OCF Ratio | 22.94 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.42, with an EV/FCF ratio of 22.07.
| EV / Earnings | 81.56 |
| EV / Sales | 2.07 |
| EV / EBITDA | 20.42 |
| EV / EBIT | 29.03 |
| EV / FCF | 22.07 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.42.
| Current Ratio | 3.01 |
| Quick Ratio | 2.31 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 3.12 |
| Debt / FCF | 3.30 |
| Interest Coverage | 2.31 |
Financial Efficiency
Return on equity (ROE) is 3.65% and return on invested capital (ROIC) is 6.76%.
| Return on Equity (ROE) | 3.65% |
| Return on Assets (ROA) | 3.47% |
| Return on Invested Capital (ROIC) | 6.76% |
| Return on Capital Employed (ROCE) | 6.77% |
| Weighted Average Cost of Capital (WACC) | 4.73% |
| Revenue Per Employee | 788,155 |
| Profits Per Employee | 20,003 |
| Employee Count | 407 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.76 |
Taxes
In the past 12 months, Pharming Group has paid 5.73 million in taxes.
| Income Tax | 5.73M |
| Effective Tax Rate | 41.29% |
Stock Price Statistics
The stock price has increased by +3.31% in the last 52 weeks. The beta is 0.06, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +3.31% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.32 |
| Relative Strength Index (RSI) | 43.40 |
| Average Volume (20 Days) | 13,712,220 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 320.78 million and earned 8.14 million in profits. Earnings per share was 0.01.
| Revenue | 320.78M |
| Gross Profit | 277.54M |
| Operating Income | 22.19M |
| Pretax Income | 13.87M |
| Net Income | 8.14M |
| EBITDA | 28.78M |
| EBIT | 22.19M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 138.54 million in cash and 99.17 million in debt, with a net cash position of 39.38 million or 0.06 per share.
| Cash & Cash Equivalents | 138.54M |
| Total Debt | 99.17M |
| Net Cash | 39.38M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 236.76M |
| Book Value Per Share | 0.33 |
| Working Capital | 164.07M |
Cash Flow
In the last 12 months, operating cash flow was 30.66 million and capital expenditures -577,698, giving a free cash flow of 30.08 million.
| Operating Cash Flow | 30.66M |
| Capital Expenditures | -577,698 |
| Depreciation & Amortization | 6.51M |
| Net Borrowing | -14.14M |
| Free Cash Flow | 30.08M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 86.52%, with operating and profit margins of 6.92% and 2.54%.
| Gross Margin | 86.52% |
| Operating Margin | 6.92% |
| Pretax Margin | 4.32% |
| Profit Margin | 2.54% |
| EBITDA Margin | 8.97% |
| EBIT Margin | 6.92% |
| FCF Margin | 9.49% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.83% |
| Shareholder Yield | -12.83% |
| Earnings Yield | 1.16% |
| FCF Yield | 4.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 3.74 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.74 |
| Piotroski F-Score | 6 |